TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03614039

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter Forte
Description: Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03932045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYB Filler (SF-01)
Description: Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellansé M
Description: Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
Study: NCT03270254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: light activated dye photodynamic therapy (PDT)
Description: light activated dye photodynamic therapy-PDT to periodontal pockets
Study: NCT02658656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReWalk 6.0
Description: Exoskeletal Assisted Walking Device
Study: NCT02558946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Physical Therapy
Description: The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
Study: NCT04164667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental and physical (MAP) training intervention
Description: In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental and physical (MAP) training intervention
Description: In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise.
Study: NCT00503789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fecal bacteria analysis
Description: ad lib feeding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal bacteria analysis
Description: ad lib feeding

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fecal bacteria analysis
Description: ad lib feeding
Study: NCT02662309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Intravenous infusion
Study: NCT00824070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gatifloxacin
Description: Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Study: NCT02723318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to Referrals to Social Services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Referrals to Social Services
Study: NCT00249288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate
Description: Folic acid taken as 2, 1mg capsule daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken as 2, 1mg capsule daily for 12 weeks
Study: NCT03024580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 160Mg Tablet
Description: Megestrol acetate 160 mg PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole 1Mg Tablet
Description: Anastrozole 1 mg PO daily OR
Study: NCT02000388

Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac Tromethamine
Study: NCT03673228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Patients in both arms will be encouraged to receive NRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Patients in both arms will be encouraged to receive NRT
Study: NCT01558375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
Study: NCT03822819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic cocktail capsules
Description: Daily uptake of probiotic cocktail for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: Daily uptake of placebo capsule for three weeks
Study: NCT01853085

Intervention type: DRUG
Intervention: Bimatoprost Ophthalmic Solution
Description: Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
Study: NCT04480580

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Ab
Description: Patient test for specific antibodies for SARS-CoV-2
Study: NCT02443129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging
Study: NCT02000388

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study: NCT01573663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol and Levodropropizine
Description: Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol
Description: Ambroxol HCl 30mg, PO, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodropropizine
Description: Levodropropizine 60mg, PO, single dose
Study: NCT01406080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
Study: NCT01534845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (Temodal)
Description: RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
Study: NCT01875562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Pill, 3.75 g, twice per day, four weeks
Study: NCT04345107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
Study: NCT04328727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Tablet 25mg and 12.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin (r-ATG)
Description: r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
Study: NCT04328727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A (CsA)
Description: CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
Study: NCT04345107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
Study: NCT03024580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tablet
Description: Letrozole 2.5 mg PO daily OR
Study: NCT04345107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-009 matching placebo
Description: SY-009 matching placebo
Study: NCT01146223

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03024580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane 25 MG
Description: Exemestane 25 mg PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen 20Mg Tablet
Description: Tamoxifen 20 mg PO daily
Study: NCT02143258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stenting of the venous sinus
Description: Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
Study: NCT03024580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 50Mg Solution for Injection
Description: Fulvestrant 500 mg IM d1, d14, d28 and q28 days
Study: NCT04228822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: 25-35% of carbohydrates from total energy intake
Study: NCT02485951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central air injection
Description: Air was injected inside the trephination site in the central injection group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral air injection
Description: Air was injected at the corneal periphery outside the trephination site.
Study: NCT01602328

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AC607
Description: AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Only
Description: The dose will be calculated and recorded in the same way as for AC607.
Study: NCT05806177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD16 30mg、40mg
Description: AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AD16 Placebo 30mg、40mg
Description: AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Study: NCT01515163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Aerobic exercise training, two times a week
Study: NCT00005922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial schedule of pharmacotherapeutic reinforcement
Description: Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose control for Arm B
Description: Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
Study: NCT02312427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspending DPP-4 inhibitor, in outpatient service
Description: After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Starting DPP-4 inhibitor after treatment of heart failure
Description: After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
Study: NCT01277276

Intervention type: DEVICE
Intervention: Diffuse optical spectroscopy and Near infrared spectroscopy
Description: Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
Study: NCT06556849

Intervention type: DEVICE
Intervention: Defocus Incorporated Multiple Segments (DIMS)
Description: To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.

Intervention type: DEVICE
Intervention: Defocus Incorporated Multiple Segments (DIMS)
Description: To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.

Intervention type: DEVICE
Intervention: Defocus Incorporated Multiple Segments (DIMS)
Description: To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.

Intervention type: DEVICE
Intervention: Defocus Incorporated Multiple Segments (DIMS)
Description: To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
Study: NCT02174926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective laparoscopic sigmoid resection

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Written lifestyle guidance and fiber supplements
Study: NCT03475251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1003
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1003
Description: CS1003 to be intravenously administered at the dose level determined during the dose escalation part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
Study: NCT00480038

Intervention type: OTHER
Group type: OTHER
Intervention: WHODAS II
Description: To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
Study: NCT02512900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929, 140 mg
Description: On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
Study: NCT02312427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspending DPP-4 inhibitor after treatment of heart failure
Description: After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
Study: NCT00005922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pharmacotherapeutic protocol
Description: Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
Study: NCT03774472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT02417337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.
Study: NCT02991196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8273a + nivolumab
Description: Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
Study: NCT00660660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
Study: NCT02417337

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root Canal Treatment
Description: A standardized endodontic procedures performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study: NCT00660660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT03835468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides
Description: GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: sugar based placebo
Study: NCT02417337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol